Biotechnology company
Appears in 1 story
Wholly-owned Merck subsidiary; original developer of remigromig
Merck said Thursday its experimental eye drug remigromig hit the primary endpoint in a 984-patient trial for diabetic macular edema. Both tested doses matched ranibizumab, the long-standing standard, on visual acuity at 52 weeks.
Updated 1 hour ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
